Breast Cancer Update Research To Practice
-
- Ciencias
-
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
-
Virtual Case Library: Metastatic Triple-Negative Breast Cancer
Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.
-
Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer
Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.
-
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.
-
Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.
-
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.
-
Implications of Recent Data Sets for the Current and Future Management of Breast Cancer
Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.